Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections

References

• Pilarski L M, Andrews E J, Serra H M, Ruether B A, Mant M J. Comparative analysis of immunodeficiency in patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma. Scand J Immunol 1989; 29: 217–228
   PubMed Web of Science ®Google Scholar
• Kay N E, Leong T L, Bone N, Vesole D H, Greipp P R, Van Ness B, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23–28
   PubMed Web of Science ®Google Scholar
• Kay N E, Leong T, Bone N, Kyle R A, Greipp P R, Van Ness B, et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 1998; 100: 459–463
   PubMed Web of Science ®Google Scholar
• Kay N E, Oken M M, Kyle R, Van Ness B, Kalish L, Leong T, et al. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leuk Lymphoma 1995; 16: 351–354
   PubMed Web of Science ®Google Scholar
• Laurenti L, Piccioni P, Piccirillo N, Sora F, Chiusolo P, Garzia M, et al. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients. Leuk Lymphoma 2004; 45: 2063–2070
   PubMed Web of Science ®Google Scholar
• Akpek G, Lenz G, Lee S M, Sanchorawala V, Wright D G, Colarusso T, et al. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant 2001; 28: 1105–1109
   PubMed Web of Science ®Google Scholar
• Steingrimsdottir H, Gruber A, Bjorkholm M, Svensson A, Hansson M. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832–838
   PubMed Web of Science ®Google Scholar
• Koehne G, Zeller W, Stockschlaeder M, Zander A R. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 149–156
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, et al. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Hematol 2005; 84: 594–600
   PubMed Web of Science ®Google Scholar
• D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Parman T, Wiley M J, Wells P G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999; 5: 582–585
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950
   PubMed Web of Science ®Google Scholar
• Haslett P A, Hanekom W A, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187: 946–955
   PubMed Web of Science ®Google Scholar
• Shannon E J, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109–116
   PubMed Web of Science ®Google Scholar
• McHugh S M, Rifkin I R, Deighton J, Wilson A B, Lachmann P J, Lockwood C M, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160–167
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Karrow N A, McCay J A, Brown R D, Musgrove D L, Pettit D A, Munson A E, et al. Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol Appl Pharmacol 2000; 165: 237–244
   PubMed Web of Science ®Google Scholar
• Sampaio E P, Sarno E N, Galilly R, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699–703
   PubMed Web of Science ®Google Scholar
• Curley M J, Hussein S A, Hassoun P M. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 2002; 40: 2302–2304
   PubMed Web of Science ®Google Scholar
• Wolfler A, Bauer F, Zollner G, Weber K, Sill H, Linkesch W. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma. Haematologica 2003; 88: ELT12
   PubMedGoogle Scholar
• Twomey J J. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132: 562–565
   PubMed Web of Science ®Google Scholar
• McKenzie R S, Glenn L D, Goldsmith J C. Pneumocystis carinii pneumonia complicating multiple myeloma. Chest 1991; 99: 656–659
   PubMed Web of Science ®Google Scholar
• Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74: 40–46
   PubMed Web of Science ®Google Scholar
• Jolliff C R, Cost K M, Stivrins P C, Grossman P P, Nolte C R, Franco S M, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem 1982; 28: 126–128
   PubMed Web of Science ®Google Scholar
• Kay N, Leong T, Kyle R A, Greipp P, Van Ness B, Bone N, et al. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 1999; 33: 127–133
   PubMed Web of Science ®Google Scholar
• Tienhaara A, Pelliniemi T T. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Lab Haematol 1994; 16: 213–223
   PubMedGoogle Scholar
• Mackall C L, Fleisher T A, Brown M R, Magrath I T, Shad A T, Horowitz M E, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221–2228
   PubMed Web of Science ®Google Scholar
• Ashihara E, Shimazaki C, Yamagata N, Hirata T, Okawa K, Oku N, et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 1994; 13: 377–381
   PubMed Web of Science ®Google Scholar
• Mackall C L, Granger L, Sheard M A, Cepeda R, Gress R E. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993; 82: 2585–2594
   PubMed Web of Science ®Google Scholar
• Lindemann M, Schuett P, Moritz T, Ottinger H D, Opalka B, Seeber S, et al. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia 2005; 19: 490–492
   PubMed Web of Science ®Google Scholar
• Schutt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, et al. In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunol Immunother 2005; 54: 506–512
   PubMed Web of Science ®Google Scholar
• Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman V H, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13: 1047–1054
   PubMed Web of Science ®Google Scholar
• Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 2004; 79: 283–288
   PubMed Web of Science ®Google Scholar
• Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Dispenzieri A, Fonseca R, Lacy M Q, Geyer S, Lust J A, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276
   PubMed Web of Science ®Google Scholar
• Strupp C, Germing U, Aivado M, Kundgen A, Fenk R, Hunerliturkoglu A, et al. The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma 2005; 46: 999–1006
   PubMed Web of Science ®Google Scholar
• Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma 2005; 52: 175–181
   PubMed Web of Science ®Google Scholar
• Del Prete G. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 1992; 47: 450–455
   PubMed Web of Science ®Google Scholar
• Fassas A B, Bolanos-Meade J, Buddharaju L N, Rapoport A, Cottler-Fox M, Chen T, et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 2001; 112: 237–241
   PubMed Web of Science ®Google Scholar
• Peggs K S, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone A H, et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 2003; 9: 198–205
   PubMed Web of Science ®Google Scholar
• Yaffee H S, Greenberg M S. Herpes zoster resembling acute varicella associated with multiple myeloma. JAMA 1961; 175: 1008–1010
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F, et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672–1678
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Dykewicz C A, Longworth D L, Boeckh M, Baden L R, Rubin R H, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001; 392–421
   PubMedGoogle Scholar
• Sepkowitz K A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34: 1098–1107
   PubMed Web of Science ®Google Scholar
• Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379–386
   PubMed Web of Science ®Google Scholar
• Roblot F, Le Moal G, Godet C, Hutin P, Texereau M, Boyer E, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 2003; 47: 19–27
   PubMed Web of Science ®Google Scholar
• Mansharamani N G, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118: 712–720
   PubMed Web of Science ®Google Scholar
• Vose J M, Cabanillas F, O'Brien S, Dang N, Drapkin R, Foss F. Infectious complications of pentostatin therapy. Oncology (Williston Park) 2000; 14: 41–42
   PubMedGoogle Scholar
• Redman J R, Cabanillas F, Velasquez W S, McLaughlin P, Hagemeister F B, Swan F, Jr, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Engels E A, Rosenberg P S, Biggar R J. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984 – 1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 180: 1784–1789
   PubMed Web of Science ®Google Scholar